Information Provided By:
Fly News Breaks for November 7, 2019
PBYI
Nov 7, 2019 | 09:26 EDT
RBC Capital analyst Kennen MacKay lowered his price target on Puma Biotechnology to $13 and kept his Sector Perform rating after its Q3 results showed a miss on Nerlynx sales. The analyst warns that the print may reflect lower demand due to dose-reductions, also noting his lowered estimates in late-stage metastatic breast cancer where he sees greater competitive pressure from other HER2+ agents in that setting.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.